Business
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong sales growth of +6% at constant exchange rates in the first quarter of 2026; -5% in CHF due to the significant appreciation of the Swiss franc
Group sales were +6% at constant exchange rates (CER)1, -5% when reported in CHF and +9% in USD2, in the first three months, driven by high demand for our innovative medicines and diagnostics.Pharmaceuticals Division sales were +7% at CER, -4% when reported in CHF and +10% in USD, due to continued high growth in sales of medicines for the treatment of severe diseases; Xolair (chronic hives, food allergies), Phesgo (breast cancer), Hemlibra (haemophilia A), Vabysmo (severe eye diseases) and Ocrev
![[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong sales growth of +6% at constant exchange rates in the first quarter of 2026; -5% in CHF due to the significant appreciation of the Swiss franc](https://media.zenfs.com/en/globenewswire.com/d295bae68c32358ba6ac888e76c1cca2)
About this update from Roche Holding Ltd
[{"type":"image","alt":"F. Hoffmann-La Roche Ltd","displaySize":"","headline":null,"caption":"F. Hoffmann-La Roche Ltd","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":198,"url":"https://media.zenfs.com/en/globenewswire.com/d295bae68c32358ba6ac888e76c1cca2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/MSaNoVyiQkMLafN4Lv5PPQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI3Nw--/https://media.zenfs.com/en/globenewswire.com/d295bae68c32358ba6ac888e76c1cca2","width":300,"height":198}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Group sales were +6% at constant exchange rates (CER)1, -5% when reported in CHF and +9% in USD2, in the first three months, driven by high demand for our innovative medicines and diagnostics.","length":197,"tagName":"p"}]},{"val":[{"type":"text","content":"Pharmaceuticals Division sales were +7% at CER, -4% when reported in CHF and +10% in USD, due to continued high growth in sales of medicines for the treatment of severe diseases; Xolair (chronic hives, food allergies), Phesgo (breast cancer), Hemlibra (haemophilia A), Vabysmo (severe eye diseases) and Ocrevus (multiple sclerosis) were the top growth drivers.","length":360,"tagName":"p"}]},{"val":[{"type":"text","content":"Diagnostics Division sales were +3% at CER, -7% when reported in CHF and +7% in USD, as demand for core lab and pathology solutions more than offset the impact of healthcare pricing reforms in China.","length":199,"tagName":"p"}]},{"val":[{"type":"text","content":"Highlights:","length":11,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Positive data for: fenebrutinib for multiple sclerosis (phase III), Gazyva/Gazyvaro for an autoimmune condition affecting kidney function (phase III); and petrelintide for obesity (phase II)","length":190,"tagName":"p"}]},{"val":[{"type":"text","content":"CE mark for new Elecsys NfL blood test to detect neuroinflammation in multiple sclerosis, representing a breakthrough in disease management","length":139,"tagName":"p"}]},{"val":[{"type":"text","content":"Launch of the cobas MPX-E assay, a new 4-in-1 test to screen blood donors for HIV and hepatitis viruses","length":103,"tagName":"p"}]},{"val":[{"type":"text","content":"Launch of the AI factory to accelerate the development of new therapeutics and diagnostics solutions","length":100,"tagName"...